Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M86,271Revenue (TTM) $M21,740Net Margin (%)17.8Altman Z-Score1.7
Enterprise Value $M102,820EPS (TTM) $1.5Operating Margin %25.0Piotroski F-Score5
P/E(ttm)21.4Beneish M-Score-2.5Pre-tax Margin (%)18.2Higher ROA y-yY
Price/Book6.110-y EBITDA Growth Rate %-2.4Quick Ratio0.7Cash flow > EarningsN
Price/Sales3.85-y EBITDA Growth Rate %-12.5Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow59.8y-y EBITDA Growth Rate %53.2ROA % (ttm)6.3Higher Current Ratio y-yN
Dividend Yield %4.1PEG--ROE % (ttm)29.1Less Shares Outstanding y-yN
Payout Ratio %92.0Shares Outstanding M2,532ROIC % (ttm)19.0Gross Margin Increase y-yY

Gurus Latest Trades with AZN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

AZN is held by these investors:



AZN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ASTRAZENECA PLC10% Owner 2014-11-12Sell2,000,000$17104.59view

Quarterly/Annual Reports about AZN:

    News about AZN:

    Articles On GuruFocus.com
    Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Sever Sep 06 2017 
    AstraZeneca’s Other Pharmaceutical Products Need to Catch Up Aug 03 2017 
    Dodge & Cox Funds Comments on AstraZeneca Aug 01 2017 
    Dodge & Cox Stock Fund 2nd Quarter Commentary Aug 01 2017 
    Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection Jul 27 2017 
    Why Emmaus Might Have Just Made Itself Attractive to Big Pharma Jul 14 2017 
    AstraZeneca: 4% Dividend Yield and a Pipeline to Emerging Market Growth Jun 15 2017 
    Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
    FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadust Mar 31 2017 
    Causeway International Value Buys AstraZeneca, Gildan Mar 09 2017 

    More From Our Partners
    Bristol-Myers Gets Priority Review for Opdivo Label Expansion Oct 17 2017 - ZACKS
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK